AU740874B2 - Method for optimizing retinal and optic nerve health - Google Patents

Method for optimizing retinal and optic nerve health Download PDF

Info

Publication number
AU740874B2
AU740874B2 AU81622/98A AU8162298A AU740874B2 AU 740874 B2 AU740874 B2 AU 740874B2 AU 81622/98 A AU81622/98 A AU 81622/98A AU 8162298 A AU8162298 A AU 8162298A AU 740874 B2 AU740874 B2 AU 740874B2
Authority
AU
Australia
Prior art keywords
adrenergic receptor
composition
carbonic anhydrase
concentration
blocking agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU81622/98A
Other languages
English (en)
Other versions
AU8162298A (en
Inventor
Michael F Sugrue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800449.2A external-priority patent/GB9800449D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU8162298A publication Critical patent/AU8162298A/en
Application granted granted Critical
Publication of AU740874B2 publication Critical patent/AU740874B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU81622/98A 1997-06-26 1998-06-22 Method for optimizing retinal and optic nerve health Ceased AU740874B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5083597P 1997-06-26 1997-06-26
US60/050835 1997-06-26
GBGB9800449.2A GB9800449D0 (en) 1998-01-09 1998-01-09 Method for optimizing retinal and optic nerve health
GB9800449 1998-01-09
PCT/US1998/013038 WO1999000133A1 (fr) 1997-06-26 1998-06-22 Procede permettant d'optimiser l'etat de sante de la retine et du nerf optique

Publications (2)

Publication Number Publication Date
AU8162298A AU8162298A (en) 1999-01-19
AU740874B2 true AU740874B2 (en) 2001-11-15

Family

ID=26312917

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81622/98A Ceased AU740874B2 (en) 1997-06-26 1998-06-22 Method for optimizing retinal and optic nerve health

Country Status (5)

Country Link
EP (1) EP1024810A4 (fr)
JP (1) JP2002506461A (fr)
AU (1) AU740874B2 (fr)
CA (1) CA2294343A1 (fr)
WO (1) WO1999000133A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
AU8008300A (en) 1999-11-01 2001-05-14 Alcon Inc. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
PL199321B1 (pl) 2000-07-28 2008-09-30 Alcon Inc Kompozycje farmaceutyczne zawierające tobramycynę i gumę ksantanową
CN101310771B (zh) * 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
KR101301839B1 (ko) * 2004-09-28 2013-08-29 센주 세이야꾸 가부시키가이샤 잔탄 검 및 아미노산을 함유하는 안과용 조성물
WO2007007894A1 (fr) 2005-07-11 2007-01-18 Senju Pharmaceutical Co., Ltd. Préparation de gouttes ophtalmiques comprenant de la gomme xanthique et un terpénoïde
JP5244584B2 (ja) 2006-03-23 2013-07-24 千寿製薬株式会社 キサンタンガムおよびブドウ糖を含有する眼科用組成物
US20100063035A1 (en) 2006-12-15 2010-03-11 Nicox S.A. Carbonic anhydrase inhibitors derivatives
US8222156B2 (en) 2006-12-29 2012-07-17 Lam Research Corporation Method and apparatus for processing a substrate using plasma
JP5305710B2 (ja) * 2008-03-31 2013-10-02 株式会社ニデック ドルゾラミド塩酸塩点眼液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3068986D1 (en) * 1980-01-28 1984-09-27 Merck & Co Inc Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
JP2965267B2 (ja) * 1992-02-21 1999-10-18 アルコン ラボラトリーズ，インコーポレイテッド 局所用抗緑内障組成物
AU666957B2 (en) * 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5789435A (en) * 1995-05-22 1998-08-04 Advanced Research And Technology Institute Method to increase retinal and optical nerve head blood flow velocity in order to preserve sight

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors

Also Published As

Publication number Publication date
JP2002506461A (ja) 2002-02-26
EP1024810A4 (fr) 2003-06-11
EP1024810A1 (fr) 2000-08-09
AU8162298A (en) 1999-01-19
WO1999000133A1 (fr) 1999-01-07
CA2294343A1 (fr) 1999-01-07

Similar Documents

Publication Publication Date Title
US6949518B1 (en) Methods for treating macular degeneration with topiramate
AU715223B2 (en) Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum
EP0227494B1 (fr) Composition pharmaceutique du type subissant une transition de phase liquide-gel
US4476140A (en) Composition and method for treatment of glaucoma
AU740874B2 (en) Method for optimizing retinal and optic nerve health
JPH11504330A (ja) カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法
CN1418100A (zh) 控制视野丧失的具有5－ht活性的化合物
JPH08509205A (ja) β−シクロデキストリン誘導体及び治療剤を含んだ眼のための局所組成物
US5314909A (en) Use of non-steroidal antiiflammatory agents in macular degeneration
US5049587A (en) Ophthalmic solution for intraocular pressure adjustment
WO1989010757A1 (fr) Nouvelle preparation ophtalmique pour le traitement de glaucomes
JP2005516017A (ja) 向上した薬物動態特性を示す医薬コンジュゲート
US5578638A (en) Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US6156785A (en) Method for increasing oxygen tension in the optic nerve and retina
AU746893B2 (en) Method for increasing oxygen tension in the optic nerve and retina
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
EP1633353A1 (fr) Composition et procede de traitement de troubles maculaires
KR0159640B1 (ko) 도파민 수용기 자극제를 포함하는 근시 및 녹내장 치료용 안과 제형
Singh 2³-Factorial Design Studies to Optimize the Ophthalmic Drug Delivery
CA2005753A1 (fr) Inhibiteurs enzymatiques convertisseurs de l'angiotensine utilises dans le traitement du glaucome

Legal Events

Date Code Title Description
SREP Specification republished
TH Corrigenda

Free format text: IN VOL 15, NO 41, PAGE(S) 9131 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX IN THE NAME OF MERCK AND CO., INC., SERIAL NO. 740874, INID (72), AMEND THE INVENTOR TO READ SUGRUE, M.F.

FGA Letters patent sealed or granted (standard patent)